OasisLMS

The landscape of biomarker-driven care in non-small cell lung cancer (NSCLC) continues to evolve, yet significant variability remains in how HER2 alterations are identified, interpreted, and integrated into clinical decision-making. We are launching a new global educational campaign focused on advancing understanding of HER2 mutations and protein overexpression in NSCLC, with an emphasis on practical, real-world application across multidisciplinary teams.

This activity is designed for multidisciplinary teams of medical oncologists, surgical oncologists, pathologists, histologists, clinical radiation oncologists, pulmonologists, radiologists and interventional radiologists, translational scientists, nurses, nurse practitioners, scientists, specialty pharmacists and physician associates globally.

Through strucutred microlearning activities and social learning with clinicians, pathologists, and researchers, you should be able to:

• Identify actionable HER2 alterations using appropriate testing modalities
• Apply strategies to reduce variability in testing practices and interpretation
• Analyze factors impacting turnaround time and implement approaches to improve clinical decision-making
• Apply best practices in tissue stewardship and sample optimization
• Evaluate the evolving role of molecular tumor boards in HER2-driven care
• Analyze challenges in resource-limited settings and propose practical solutions
• Assess the applications of digital pathology tools in biomarker assessment

We would like to thank the following faculty for their contributions in helping create the learning modules and guided social learning for this program:

Christian Rolfo
Stephanie Saw
Fernando Lopez-Rios
Mihaela Aldea
Lodovica Zullo
Gustavo Faibischew Prado
Rasha Aboelhassad

Continue the discussion in our Thoracic Circle group: HER2 Learning Exchange Network for Diagnosis (LEND): Americas. This dedicated space is designed to extend learning beyond the modules by fostering an active community of practice. Through weekly polls, surveys, case-based discussions, and expert panels, participants can engage in ongoing dialogue, exchange real-world experiences, and learn directly from peers and thought leaders. Thoracic Circle creates an environment where physicians can collaboratively explore challenges, share insights, and refine approaches to HER2 testing and diagnosis in a dynamic, practice-informed setting.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.